Active substanceRimantadineRimantadine Similar drugsTo uncover Orvirem® syrup inwards d / children Remantadine® capsules inwards Olainfarm, AO Latvia Remantadine® pills inwards EN.S. PHARM, LTD. Russia Remantadine® pills inwards ROSFARM, LLC Russia Rimantadine pills inwards NGO Farmvilar, OOO Russia Rimantadine pills inwards ATOLL, LLC Russia Rimantadine pills inwards MARBIOFARM, OJSC Russia Rimantadine pills inwards TATHIMFARMPREPARATY, JSC Russia Rimantadine pills inwards MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia Rimantadine pills inwards BIOSINTEZ, PAO Russia Rimantadine pills inwards EVROFARM, CJSC Russia Rimantadine pills inwards MOSCOW ENDOCRINE FACTORY, FSUE Russia Rimantadine pills inwards UZOLE-SIBERIAN CHEMICAL PLANT, OJSC Russia Rimantadine pills inwards En.S. Pharmaceuticals, LLC Russia Rimantadine Avecsima pills inwards AVEKSIMA, JSC Russia Rimantadine Aktitab pills inwards OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia Rimantadine Kids syrup inwards d / children PHARMSTANDART-FORESTRY, OJSC Russia Dosage form: & nbspPills Composition:Active substance:Rimantadine hydrochloride - 50.0 mg;Excipients:lactose monohydrate - 74.5 mg, potato starch - 24.0 mg, magnesium stearate - 1.5 mg. Description:Tablets are white, flat-cylindrical with a bevel. Pharmacotherapeutic group:An antiviral agent. ATX: & nbspJ.05.A.C Cyclic aminesJ.05.A.C.02 Rimantadine Pharmacodynamics:Rimantadine is active against various strains of the influenza A virus.Being a weak ground, rimantadine acts by increasing the pH of the endosome, which have a membrane of vacuoles that surround the viral particles after they penetrate the cell. The prevention of acidification in these vacuoles blocks the fusion of the viral envelope with the endosome membrane, thus preventing the transfer of the viral genetic material to the cytoplasm of the cell. Rimantadine also inhibits the release of viral particles from the cell, i.e. interrupts the transcription of the viral genome. Pharmacokinetics:After oral administration rimantadine almost completely absorbed in the intestine. Absorption is slow. The connection with plasma proteins is about 40%. The volume of distribution: adults - 17-25 l / kg, children - 289 liters. Concentration in nasal secretion is 50% higher than in plasma. The maximum concentration (Сmах) of the active substance in blood plasma at a dose of 100 mg once a day - 181 ng / ml, at 100 mg twice a day - 416 ng / ml.Metabolised in the liver. The half-life is 24-36 h; 75-85% of the accepted dose is excreted by the kidneys mainly in the form of metabolites, 15% - in unchanged form.In chronic renal failure, the elimination half-life is 2-fold. In individuals with kidney failure and in the elderly, it can accumulate in toxic concentrations if the dose is not adjusted proportionately to a decrease in creatinine clearance (KK). Indications:Prevention and early treatment of influenza A in adults and children older than 7 years. Contraindications:acute liver disease;- Acute and chronic kidney disease;- thyrotoxicosis;- Sensitive sensitivity to rimantadine;- pregnancy and lactation;- children under 7 years;- with lactase deficiency, lactose intolerance, glucose-galactose malabsorption (since the formulation contains lactose). Carefully:with arterial hypertension, atherosclerosis of cerebral vessels, liver failure, epilepsy, diseases of the gastrointestinal tract. Dosing and Administration:Inside, after eating, washed down with water.Treatment of influenza should be started within 24-48 hours after the onset of symptoms of the disease.Adults on the first day are prescribed 100 mg 3 times a day; in the second and third days of 100 mg 2 times a day; on the fourth and fifth day, 100 mg once a day. On the first day of the disease, the drug can be used once in a dose of 300 mg.Children aged 7 to 10 years are prescribed 50 mg twice a day; from 11 to 14 years - 50 mg 3 times a day. Older than 14 years - doses for adults. Take for 5 days.To prevent influenza, adults are prescribed 50 mg once a day for up to 30 days. Children older than 7 years - 50 mg 1 time per day for up to 15 days. Side effects:from the digestive system: dry mouth, nausea, vomiting, loss of appetite, epigastric pain, flatulence;from the central nervous system: headache, dizziness, insomnia, impaired concentration, drowsiness, anxiety, increased excitability, fatigue;Other: Hyperbilirubinemia, allergic reactions (skin rash, itching, urticaria). Overdose:Symptoms: excitement, hallucinations, arrhythmia.Treatment: gastric lavage, symptomatic therapy: measures to maintain vital functions. Rimantadine partially excreted in hemodialysis. Interaction:Rimantadine reduces the effectiveness of antiepileptic drugs.Paracetamol and ascorbic acid reduce the maximum concentration of rimantadine in blood plasma by 11%.Cimetidine reduces the clearance of rimantadine by 18%.Adsorbents, astringents and enveloping agents reduce the absorption of rimantadine.Urine alkaline agents (acetazolamide, sodium hydrogen carbonate and others) increase the effectiveness of rimantadine due to a decrease in its excretion by the kidneys. Special instructions:With the use of rimantadine, an exacerbation of chronic comorbidity may occur. In elderly patients with hypertension, the risk of hemorrhagic stroke increases.With a history of epilepsy and ongoing anticonvulsant therapy with rimantadine, the risk of epileptic seizures increases. In such cases rimantadine apply in a dose of 100 mg per day simultaneously with anticonvulsant therapy.Prophylactic reception is effective at contacts with the sick, with the spread of infection in closed collectives and at a high risk of the disease during the flu epidemic.Perhaps the emergence of drug-resistant viruses. Effect on the ability to drive transp. cf. and fur:During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions. Form release / dosage:Tablets 50 mg. Packaging:10 tablets per contour cell pack. 1 or 2 contourcell packs with instructions for use in a pack of cardboard. Storage conditions:In the dark place at a temperature of no higher than 25 0C. Keep out of the reach of children. Shelf life:5 years. Do not use after the expiration date printed on the package. Terms of leave from pharmacies:Without recipe Registration number:P N002605 / 01-2003 Date of registration:23.07.2008 The owner of the registration certificate:MOSCOW ENDOCRINE FACTORY, FSUE MOSCOW ENDOCRINE FACTORY, FSUE Russia Manufacturer: & nbspMOSCOW ENDOCRINE FACTORY, FSUE Russia Information update date: & nbsp22.09.2015 Illustrated instructions × Illustrated instructions Instructions